The device industry, specialty societies and other stakeholders say CMS should open up coverage for all FDA-approved radiopharmaceuticals for use in positron emission tomography as soon as they come on the market and not limit them to the four diagnostic agents singled out for Medicare coverage.
“We strongly believe that future FDA approved imaging agents should not be non-covered by Medicare following FDA approval,” the World Molecular Imaging Society writes in Aug. 8 comments to CMS
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?